Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients (PRESERVE)

2. november 2026 opdateret af: Swedish Orphan Biovitrum

A 2-year, Single-arm, Multi-center Study to Explore the Efficacy and Safety of Pegcetacoplan in Preventing Disease Recurrence in Adolescent and Adult Kidney Transplant Recipients With C3 Glomerulopathy or Primary Immune-complex Membranoproliferative Glomerulonephritis

To assess the efficacy and safety of pegcetacoplan for the prevention of recurrent C3G or primary IC-MPGN in kidney transplant recipients

Studieoversigt

Detaljeret beskrivelse

The PRESERVE study is a Phase 3b, multicenter, single-arm, open-label clinical trial designed to explore the efficacy and safety of pegcetacoplan in preventing or delaying the recurrence of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) following kidney transplantation. Recurrence of these diseases after transplantation is common and can lead to graft dysfunction and loss. Pegcetacoplan is a complement C3/C3b inhibitor that has demonstrated activity in patients with native kidney disease and recurrent disease after transplantation. The study aims to assess whether initiating pegcetacoplan at the time of kidney transplantation, before recurrence occurs, may delay the recurrence and support long-term graft outcomes. Participants will receive pegcetacoplan in addition to standard post-transplant care and will be followed to evaluate disease recurrence, kidney function, graft outcomes, safety, and tolerability.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

30

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Pernambuco
      • Recife, Pernambuco, Brasilien, 52010-010
        • Real Hospital Português
    • São Paulo
      • Botucatu, São Paulo, Brasilien, 18618-970
        • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
      • São Paulo, São Paulo, Brasilien, 05403-000
        • Hospital das Clinicas da Faculdade de Medicina da USP - HCFMUSP
    • Alberta
      • Edmonton, Alberta, Canada, T6G 2R7
        • University of Alberta - Faculty of Medicine & Dentistry
    • British Columbia
      • Vancouver, British Columbia, Canada, V6Z 1Y6
        • St. Paul's Hospital
    • Ontario
      • London, Ontario, Canada, N6A 5A5
        • London Health Sciences Centre (LHSC) - University Hospital
      • Toronto, Ontario, Canada, M5G 2C4
        • Toronto General Hospital
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • McGill University Health Centre Research Institute
    • Greater London
      • London, Greater London, Det Forenede Kongerige, NW3 2QG
        • Royal Free Hospital
      • London, Greater London, Det Forenede Kongerige, W12 0HS
        • Hammersmith Hospital
    • Greater Manchester
      • Manchester, Greater Manchester, Det Forenede Kongerige, M13 9WL
        • Manchester Royal Infirmary
    • Tyne & Wear
      • Newcastle upon Tyne, Tyne & Wear, Det Forenede Kongerige, NE7 7DN
        • Freeman Hospital
      • Helsinki, Finland, 290
        • Helsinki University Central Hospital
    • Bas Rhin
      • Strasbourg, Bas Rhin, Frankrig, 67091
        • CHU Strasbourg - Nouvel Hôpital Civil
    • Haute Garonne
      • Toulouse, Haute Garonne, Frankrig, 31059
        • Hopital Rangueil
    • Herault
      • Montpellier, Herault, Frankrig, 34000
        • Hopital Lapeyronie pt
    • Nord
      • Lille, Nord, Frankrig, 59037
        • Hopital Claude Huriez - CHU Lille
    • Paris
      • Paris, Paris, Frankrig, 75015
        • Hôpital Necker - Enfants Malades
    • Rhone
      • Lyon, Rhone, Frankrig, 69437
        • Hopital Edouard Herriot - CHU Lyon
    • Bari
      • Bari, Bari, Italien, 70124
        • Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
    • Bergamo
      • Bergamo, Bergamo, Italien, 24127
        • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
    • Roma
      • Roma, Roma, Italien, 165
        • Ospedale Pediatrico Bambino Gesù
      • Roma, Roma, Italien, 168
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      • Riyadh, Saudi Arabien, 11211
        • King Faisal Specialist Hospital & Research Center
      • Lausanne, Schweiz, 1011
        • Centre Hospitalier Universitaire Vaudois (CHUV)
    • Barcelona
      • Barcelona, Barcelona, Spanien, 8035
        • Hospital Universitari Vall d'Hebron - VHIR
    • La Coruña
      • A Coruña, La Coruña, Spanien, 15006
        • Complejo Hospitalario Universitario A Coruña
    • Madrid
      • Madrid, Madrid, Spanien, 28041
        • Hospital Universitario 12 de Octubre
    • Málaga
      • Málaga, Málaga, Spanien, 29010
        • Hospital Regional Universitario de Malaga
    • Vizcaya
      • Barakaldo, Vizcaya, Spanien, 48903
        • Hospital de Cruces
    • Lower Saxony
      • Hanover, Lower Saxony, Tyskland, 30625
        • Medizinische Hochschule Hannover
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Tyskland, 50937
        • Universitaetsklinikum Koeln
      • Essen, North Rhine-Westphalia, Tyskland, 45147
        • Universitaetsklinikum Essen

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

12 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female patients with a diagnosis of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) who are planning to undergo kidney transplantation because of the disease.
  • Have a high risk of disease recurrence following kidney transplantation, based on either having a previous kidney allograft loss due to recurrence of C3G or primary IC-MPGN, or assessed as having a high risk by the investigator based on other clinical information.
  • Is fully vaccinated and up to date with their vaccinations against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B, in accordance with local guidelines, at the time of initiating pegcetacoplan.

Exclusion Criteria:

  • A known secondary cause for MPGN, including but not limited to monoclonal gammopathy of clinical significance, hepatitis B, hepatitis C, or autoimmune cryoglobulinemia.
  • History of invasive meningococcal disease.
  • History of malignancy, except for the following: cured basal or squamous cell skin cancer, curatively treated in situ disease, or currently malignancy-free and has been off-treatment for the malignancy for at least 5 years.
  • Hypersensitivity to pegcetacoplan or any of its excipients.
  • Known or suspected hereditary fructose intolerance.
  • Any other medical condition which, in the opinion of the Investigator, makes the participant unsuitable for inclusion.
  • Use of a complement inhibitor for the treatment of C3G or primary IC-MPGN within 1 month prior to the scheduled kidney transplantation surgery.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Pegcetacoplan

Pegcetacoplan, a complement C3/C3b inhibitor, administered according to the study protocol in kidney transplant recipients with high risk of recurring C3G or primary IC-MPGN

Dose amount based on age and weight Subcutaneous infusion twice-a-week. Adult participants aged 18 years or older at enrolment: 1080 mg

Adolescent participants aged 12 to 17 years at enrolment:

  • Weight ≥50 kg: 1080 mg
  • Weight 35 to <50 kg: 648 mg 1st dose, then 810 mg subsequently
  • Weight 30 to <35 kg: 540 mg for the first 2 doses, then 648 mg subsequently
Andre navne:
  • APL-2
  • Aspaveli
  • Empaveli

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Occurrence of Clinically Significant Recurrent Disease
Tidsramme: Within 2 years after kidney transplantation

Histological evidence of recurrent disease based on the histopathological assessment of the kidney biopsy

Within 2 years after kidney transplantation

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to Onset of Clinically Significant Disease Recurrence
Tidsramme: Up to 2 years after kidney transplantation

To explore the impact of pegcetacoplan on time to clinically significant recurrence of C3G or primary IC-MPGN after kidney transplantation

Up to 2 years after kidney transplantation

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Studieleder: Study Physician, Swedish Orphan Biovitrum AB (publ)

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

21. januar 2027

Primær færdiggørelse (Anslået)

17. januar 2031

Studieafslutning (Anslået)

17. januar 2031

Datoer for studieregistrering

Først indsendt

21. oktober 2026

Først indsendt, der opfyldte QC-kriterier

21. oktober 2026

Først opslået (Faktiske)

27. oktober 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • Sobi.PEGCET-404
  • 2026-526392-39-00 (Ctis)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers may request access to patient level data and related study documents.

All requests are evaluated by a cross functional panel of experts within Sobi. Patient level data will be anonymized and study documents, if applicable, will be redacted to protect the privacy of trial participants.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner